Neuland Laboratories Limited (BOM: 524558)
India
· Delayed Price · Currency is INR | Market Cap | 178.35B |
| Revenue (ttm) | 15.28B |
| Net Income (ttm) | 2.80B |
| Shares Out | 12.83M |
| EPS (ttm) | 217.98 |
| PE Ratio | 63.77 |
| Forward PE | 53.30 |
| Dividend | 14.00 (0.10%) |
| Ex-Dividend Date | Jul 12, 2024 |
| Volume | 1,590 |
| Open | 14,752 |
| Previous Close | 14,795 |
| Day's Range | 14,351 - 14,845 |
| 52-Week Range | 4,928 - 18,090 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 4, 2025 |
About Neuland Laboratories
Neuland Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, as well as peptide synthesis services. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. [Read more]
Financial Performance
In 2023, Neuland Laboratories's revenue was 15.59 billion, an increase of 30.81% compared to the previous year's 11.91 billion. Earnings were 3.00 billion, an increase of 83.51%.
Financial StatementsNews
Mixed trends in November CDRMO exports, prefer Syngene and Neuland Labs over Divis Labs and Laurus Labs
Goldman Sachs notes mixed trends in November for Indian contract development and manufacturing organizations (CDMOs). Monthly export figures showed variability, with Neuland Labs recording a sharp 276...
Neuland Labs exports surge threefold YoY in November, 43.1% MoM growth
Neuland Labs reported exceptional export performance in November 2024, with exports growing threefold year-over-year (YoY). The company also witnessed robust month-on-month (MoM) growth of 43.1%, posi...
Neuland Labs shares down over 5% as 4.8 lakh shares worth Rs 747 crore change hands in block trade
Neuland Laboratories’ shares dropped over 5% in intraday trading today following a significant block deal that saw the exchange of 4.8 lakh shares, amounting to 3.8% of the company’s equity. Here’s a ...
Neuland Laboratories shares surge nearly 10% amid AbbVie’s phase 2 setback on schizophrenia drug
Neuland Laboratories Ltd. witnessed a significant boost in its stock price today, surging 10% and trading at ₹15,107.00 as of 9:31 AM on the NSE. The stock’s upward momentum comes as rival AbbVie face...
Goldman Sachs maintains buy on Neuland Labs, raises target to Rs 15,250; sees 7% upside potential
Goldman Sachs has reiterated its buy rating on Neuland Laboratories, increasing the target price from ₹13,750 to ₹15,250, indicating a 7% upside from the current market price of ₹14,220. The company p...
Neuland Laboratories shares plunge over 13% after disappointing Q2 FY25 results; revenue down 25.1% YoY to ₹315.2 crore, PAT declines 64.1%
Neuland Laboratories Ltd, a prominent name in the pharmaceutical sector, experienced a sharp decline in its stock price, dropping over 13% following the release of its Q2 FY25 financial results. The c...
Neuland Laboratories Q2 FY25 Results: Revenue down 25.1% YoY to ₹315.2 crore, PAT declines 64.1%
Neuland Laboratories Ltd, a leading player in the pharmaceutical sector, announced its financial results for the second quarter of FY25, ending September 30, 2024. The company witnessed a decline in i...
Stocks to Buy This Diwali: AngelOne sees Neuland Laboratories reaching ₹19,580, with 25% growth potential
AngelOne has highlighted Neuland Laboratories Ltd as a promising stock pick for Diwali 2024, with a target price of ₹19,580. Currently trading at ₹15,667, Neuland Laboratories offers a potential upsid...
B&K on Neuland Labs: Maintains Buy call, raises target price to Rs 20,000, sees 40% upside
B&K Securities has reiterated its Buy rating on Neuland Laboratories, raising the target price to Rs 20,000 from the previous Rs 11,700, indicating a 40% upside from the current market price of Rs 14,...
Goldman Sachs initiates ‘buy’ call on Neuland Labs, check target price
Goldman Sachs has issued a ‘buy’ call on Neuland Laboratories, setting a target price of ₹12,975 per share. The recent US FDA approval for Bristol-Myers Squibb’s (BMS) schizophrenia drug, which involv...
Q1 2025 Neuland Laboratories Ltd Earnings Call Transcript
Q1 2025 Neuland Laboratories Ltd Earnings Call Transcript